These findings suggest SNHG3 as a potential therapeutic target and biomarker for predicting sorafenib response in HCC, with increased SNHG3 expression correlating with poor survival outcomes and reduced treatment response. The gene discussed is SNHG3; the disease is hepatocellular carcinoma.